Figure 1.

Patient disposition through week 52. *Includes withdrawal by patient, lost to follow-up, protocol violation, non-compliance, other. ^†Includes patients initially randomised to placebo, who met early escape criteria and were then randomised to apremilast at week 16. ^‡Includes patients initially randomised to placebo who were then randomised to apremilast at week 24 for the active treatment phase (week 24–52). AE, adverse event.